MX2021001083A - Regimen posologico para anticuerpos biespecificos contra bcma-cd3. - Google Patents

Regimen posologico para anticuerpos biespecificos contra bcma-cd3.

Info

Publication number
MX2021001083A
MX2021001083A MX2021001083A MX2021001083A MX2021001083A MX 2021001083 A MX2021001083 A MX 2021001083A MX 2021001083 A MX2021001083 A MX 2021001083A MX 2021001083 A MX2021001083 A MX 2021001083A MX 2021001083 A MX2021001083 A MX 2021001083A
Authority
MX
Mexico
Prior art keywords
bcma
antibody construct
bispecific antibodies
dosing regimen
treatment
Prior art date
Application number
MX2021001083A
Other languages
English (en)
Inventor
Gerd Munzert
Gerhard Zugmaier
Max Topp
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of MX2021001083A publication Critical patent/MX2021001083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a un constructo de anticuerpo que comprende un primer dominio que se une a BCMA y un segundo dominio que se une a CD3, para su uso en el tratamiento o mejora de una neoplasia positiva para BCMA, donde el constructo de anticuerpo se administra en una dosis específica en al menos un ciclo, donde un ciclo comprende un período específico de administración del constructo de anticuerpo. Además, la invención se refiere a un método para el tratamiento de una neoplasia positiva para BCMA que comprende administrar una cantidad específica de tal constructo de anticuerpo y el uso de tal constructo de anticuerpo para la fabricación de un medicamento para el tratamiento de una neoplasia positiva para BCMA.
MX2021001083A 2018-07-31 2019-07-30 Regimen posologico para anticuerpos biespecificos contra bcma-cd3. MX2021001083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712357P 2018-07-31 2018-07-31
PCT/EP2019/070455 WO2020025596A1 (en) 2018-07-31 2019-07-30 Dosing regimen for bcma-cd3 bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2021001083A true MX2021001083A (es) 2021-03-31

Family

ID=67513510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001083A MX2021001083A (es) 2018-07-31 2019-07-30 Regimen posologico para anticuerpos biespecificos contra bcma-cd3.

Country Status (9)

Country Link
US (1) US20210284732A1 (es)
EP (1) EP3830122A1 (es)
JP (1) JP2021532073A (es)
AU (1) AU2019316164A1 (es)
CA (1) CA3105729A1 (es)
DE (1) DE102019120667A1 (es)
MX (1) MX2021001083A (es)
TW (1) TW202019477A (es)
WO (1) WO2020025596A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240050646A1 (en) * 2020-12-22 2024-02-15 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
US20220193235A1 (en) * 2020-12-22 2022-06-23 Regina E. HERZLINGER Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion
US11806507B2 (en) * 2020-12-22 2023-11-07 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
PT1071752E (pt) 1998-04-21 2003-11-28 Micromet Ag Polipeptidos especificos para cd19xcd3 e suas utilizacoes
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
ATE251181T1 (de) 1998-07-28 2003-10-15 Micromet Ag Heterominikörper
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
LT2520590T (lt) 2007-04-03 2018-09-10 Amgen Research (Munich) Gmbh Susijusioms rūšims specifinis rišantis domenas
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
US9150644B2 (en) * 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
CN103748114B (zh) 2011-08-23 2017-07-21 罗切格利卡特公司 T细胞活化性双特异性抗原结合分子
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP3424952A1 (en) 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
EP3733710A1 (en) 2013-09-25 2020-11-04 Amgen, Inc Hetrodimeric v-c-fc-v-c antibody
PE20180795A1 (es) * 2015-08-17 2018-05-09 Janssen Pharmaceutica Nv Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
KR20180103084A (ko) * 2016-02-03 2018-09-18 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물

Also Published As

Publication number Publication date
US20210284732A1 (en) 2021-09-16
TW202019477A (zh) 2020-06-01
EP3830122A1 (en) 2021-06-09
WO2020025596A1 (en) 2020-02-06
DE102019120667A1 (de) 2020-02-06
AU2019316164A1 (en) 2021-01-21
CA3105729A1 (en) 2020-02-06
JP2021532073A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
HRP20210440T1 (hr) Kombinirana terapija za rak
HRP20191162T1 (hr) Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
CR20160319A (es) Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
EA037351B8 (ru) Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
JP2014111603A5 (es)
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2020007697A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos.
RU2017134443A (ru) Способ лечения с применением традипитанта
HRP20240159T1 (hr) Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
MX2022001721A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos.
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
RU2018127640A (ru) Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2022005628A (es) Regimen de dosificacion para agentes anti-bcma.